![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Wobrock Thomas Soyka Michael
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.10, Iss.3, 2009-02, pp. : 353-367
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Treatment of Patients with Schizophrenia and Substance Abuse Disorders
Current Pharmaceutical Design, Vol. 10, Iss. 18, 2004-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmacotherapy of Dual Substance Abuse and Dependence
CNS Drugs, Vol. 21, Iss. 3, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Substance Misuse in Patients with Schizophrenia: Epidemiology and Management
Drugs, Vol. 62, Iss. 5, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Opioid Therapy in Patients with a History of Substance Abuse
CNS Drugs, Vol. 18, Iss. 1, 2004-01 ,pp. :